6-chloro-12a-hydroxy-5H-benzophenoxazin-5-one | 73396-99-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 6-chloro-12a-hydroxy-5H-benzophenoxazin-5-one
• 英文别名: 6-chloro-12a-hydroxy-5H-benzo[c]phenoxazin-5-one；6-chloro-12a-hydroxy-7H-benzo[c]phenoxazin-5-one
• CAS: 73396-99-3
• 化学式: C₁₆H₁₀ClNO₃
• 分子量: 299.713
• InChiKey: PJIJVIHBLJLRFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基苯酚 、 2,3-二氯-1,4-萘醌 、 6-chloro-12a-hydroxy-5H-benzophenoxazin-5-one 、 乙醇 、 乙醇 、 盐酸 以66%的产率得到
  参考文献：
  名称：

  AGARWAL N. L.; SCHAEFER W., J. ORG. CHEM., 1980, 45, NO 11, 2155-2161

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氨基苯酚 、 2,3-二氯-1,4-萘醌 、 甲醇 以18%的产率得到
  参考文献：
  名称：

  AGARWAL N. L.; SCHAEFER W., J. ORG. CHEM., 1980, 45, NO 11, 2155-2161

  摘要：

  DOI：

文献信息

• Quinone chemistry. Reaction of 2,3-dichloro-1,4-naphthoquinone with o-aminophenols under various conditions
  作者：Nand L. Agarwal、Wolfram Schaefer

  DOI：10.1021/jo01299a024

  日期：1980.5
• COMPOSITIONS AND METHODS FOR TREATING ALZHEIMERS DISEASE
  申请人：Puglielli Luigi

  公开号：US20120329789A1

  公开（公告）日：2012-12-27

  Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
• Compositions and Methods for Treating Alzheimers Disease
  申请人：Wisconsin Alumni Research Foundation

  公开号：US20150182477A1

  公开（公告）日：2015-07-02

  Pharmaceutical compositions for treating Alzheimer's disease are disclosed. The pharmaceutical compositions include a compound having the general formula: and a pharmaceutically acceptable carrier. Methods for treating Alzheimer's disease, inhibiting ATase I and/or ATase 2, reducing the activity of BACE1, reducing the level of amyloid β-peptide (Aβ), and/or reducing the level of APP intracellular domain peptide (AICD) by administering such compositions are also disclosed.
• US8980884B2
  申请人：——

  公开号：US8980884B2

  公开（公告）日：2015-03-17
• US9522124B2
  申请人：——

  公开号：US9522124B2

  公开（公告）日：2016-12-20